Abstract | OBJECTIVE: METHODS: RESULTS: Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. CONCLUSION:
|
Authors | Ralph C Williams Jr, Kazumitsu Sugiura, Eng M Tan |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 50
Issue 4
Pg. 1239-47
(Apr 2004)
ISSN: 0004-3591 [Print] United States |
PMID | 15077307
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Autoantibodies
- Biomarkers
- Immunoglobulin G
- Microtubule-Associated Proteins
|
Topics |
- Adolescent
- Adult
- Aged
- Autoantibodies
(blood)
- Biomarkers
- Brain Injuries
(immunology)
- Female
- Humans
- Immunoglobulin G
(blood)
- Lupus Vasculitis, Central Nervous System
(immunology)
- Male
- Microtubule-Associated Proteins
(immunology)
- Middle Aged
- Nervous System Diseases
(immunology)
- Neurons
(immunology)
- Spinal Cord Injuries
(immunology)
|